CPL @1097 (97.5%) on 19-jan-2018 [ "common side effects with _" "_ is a prescription medicine" "TNF-blocking agents , including _" "medication called _" "period patient was treated with _" "same period patient was treated with _" "Mothers It is not known whether _" "open-label treatment with _" "patient was treated with _" "continued treatment with _" "drugs like _" "nursing infants from _" ] using remicade
SEAL @179 (87.5%) on 15-dec-2010 [ 123 ] using remicade
MBL @329 (100.0%) on 03-jul-2011 [ Promotion of drug:remicade drughassideeffect disease:side_effects ]
CPL @1111 (62.4%) on 25-jun-2018 [ "common side effects with _" "drug called _" "_ is a prescription medicine" "TNF-blocking agents , including _" "medication called _" "period patient was treated with _" "same period patient was treated with _" "severe hypersensitivity reactions to _" "Mothers It is not known whether _" "patient assistance for _" "open-label treatment with _" "patient was treated with _" "continued treatment with _" "_ is currently indicated for" "_ is a monoclonal antibody" "post-marketing experience with _" "drugs like _" "nursing infants from _" ] using remicade
SEAL @178 (64.9%) on 14-dec-2010 [ 123 ] using remicade
SEAL @521 (96.9%) on 28-feb-2012 [ 12345 ] using (remicade, side_effects)
CPL @1094 (98.4%) on 01-jan-2018 [ "arg1 was generally well tolerated and arg2" "arg1 is generally well tolerated and arg2" "arg1 such as dosage and arg2" "arg1 has been associated with different arg2" "arg1 and suffered arg2" "arg1 has serious potential arg2" ] using (remicade, side_effects)
NELL has only weak evidence for items listed in grey
SEAL @521 (96.9%) on 28-feb-2012 [ 12345 ] using (remicade, side_effects)
CPL @1094 (98.4%) on 01-jan-2018 [ "arg1 was generally well tolerated and arg2" "arg1 is generally well tolerated and arg2" "arg1 such as dosage and arg2" "arg1 has been associated with different arg2" "arg1 and suffered arg2" "arg1 has serious potential arg2" ] using (remicade, side_effects)